Clinical Trials on FLT3-mutated Acute Myeloid Leukemia in United Kingdom
Total 3147 results
-
Novartis PharmaceuticalsRecruitingFLT3-mutated Acute Myeloid LeukemiaKorea, Republic of, Germany, Italy, Turkey, Czechia, Jordan, Slovenia, Austria, Poland, Japan, Russian Federation, United States, Greece
-
Astellas Pharma Global Development, Inc.RecruitingAcute Myeloid Leukemia (AML) | FLT3-mutated Acute Myeloid LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedSecondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With Gene Mutations | FLT3 Tyrosine Kinase Domain Point MutationUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteJazz PharmaceuticalsRecruitingAcute Myeloid Leukemia With FLT3/ITD MutationUnited States
-
Arog Pharmaceuticals, Inc.CompletedPhase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsRelapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States
-
Kronos BioTerminatedNucleophosmin 1-mutated Acute Myeloid LeukemiaIsrael, Spain, France, United States, Czechia, Hungary, Korea, Republic of, Germany, Italy, Poland, Brazil, Canada
-
Astellas Pharma Global Development, Inc.No longer availableAcute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) MutationsAustralia, Italy, United Kingdom
-
AstraZenecaCompletedAcute Myeloid LeukaemiaUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Refractory Acute LeukemiaUnited States
-
Astellas Pharma Global Development, Inc.CompletedAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) MutationUnited States
-
National Cancer Institute (NCI)CompletedTherapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | FLT3 Gene Mutation | Acute Promyelocytic Leukemia With PML-RARA | Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1United States
-
Great Ormond Street Hospital for Children NHS Foundation...Wellcome TrustRecruitingRelapsed Acute Myeloid LeukaemiaUnited Kingdom
-
Arog Pharmaceuticals, Inc.RecruitingRelapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States, Germany, Spain, Italy, France, Canada
-
National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia With FLT3/ITD MutationUnited States
-
Arog Pharmaceuticals, Inc.CompletedNewly Diagnosed AML With FLT3 Activating MutationsUnited States
-
Astellas Pharma Global Development, Inc.RecruitingAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)United States, Canada, Germany, Italy, Spain, United Kingdom, France
-
Uma BorateRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 MutationUnited States
-
Astellas Pharma Global Development, Inc.Active, not recruitingAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) MutationUnited States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesUnited States
-
Novartis PharmaceuticalsNo longer availableAcute Myeloid Leukemia (AML) With | FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)United States
-
Astellas Pharma Global Development, Inc.CompletedAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) MutationTaiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
-
Northwestern UniversityNational Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...Active, not recruitingRecurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 Internal Tandem DuplicationUnited States
-
University Hospital Southampton NHS Foundation...Genzyme, a Sanofi CompanyCompletedMyelodysplasia | Acute Myeloid LeukaemiaUnited Kingdom
-
Cell Medica LtdUniversity College, London; Cell Therapy CatapultCompletedAcute Myeloid Leukaemia | Chronic Myeloid LeukaemiaUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedFLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...United States
-
Kura Oncology, Inc.RecruitingNeoplasms by Histologic Type | Acute Myeloid Leukemia | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | AML | Acute Leukemia | Hematologic Malignancy | NPM1 Mutation | AML With Mutated NPM1 | KMT2Ar | MLL RearrangementUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonRecruiting
-
Royal Marsden NHS Foundation TrustTC BiopharmUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyActive, not recruitingAcute Myeloid LeukaemiaUnited States, Australia, France, Spain
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedAcute Myeloid LeukaemiaFrance, United States, Australia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.RecruitingAcute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Hematologic and Lymphocytic Disorder | Acute Myeloid Leukemia in Remission | FLT3 Gene Mutation | Minimal Residual Disease PersistenceUnited States
-
AstraZenecaTerminatedAcute Myeloid LeukaemiaUnited States, Australia
-
University of BirminghamAssistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...RecruitingAcute Myeloid LeukaemiaFrance, Switzerland, United Kingdom, New Zealand, Australia, Ireland
-
GlaxoSmithKlineTerminatedLeukaemia, Myelocytic, AcuteUnited States, Australia, Canada
-
TC BiopharmRecruiting
-
Syndax PharmaceuticalsRecruitingAcute Myeloid LeukemiasUnited States
-
University of BirminghamJazz Pharmaceuticals; Adienne SA; IMPACT (funded by NHS Blood & Transplant, Anthony...Active, not recruitingAcute Myeloid Leukaemia | High-risk Myelodysplastic SyndromeUnited Kingdom
-
SanofiTerminatedAcute Myeloid LeukaemiaUnited States
-
Kura Oncology, Inc.RecruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Myeloid Sarcoma | Acute Myeloid Leukemia Recurrent | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia | Refractory AML | NPM1 Mutation | Mixed Lineage Leukemia Gene Mutation | AML With Mutated NPM1 | KMT2ArUnited States
-
Institut de Recherches Internationales ServierRecruitingMyelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic MalignanciesUnited States, France
-
OnxeoCompletedAcute Myeloid LeukemiaUnited Kingdom, Germany, France
-
Cardiff UniversityExperimental Cancer Medicine Centres; Leukaemia & Lymphoma Research GroupCompletedHigh Risk Myelodysplastic Syndrome | Acute Myeloid LeukaemiaUnited Kingdom
-
GlaxoSmithKlineCompletedLeukaemia, Myelocytic, AcuteUnited States
-
Cell Medica LtdUniversity College, London; Cell Therapy CatapultCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)United Kingdom, Germany, Belgium
-
Akinion Pharmaceuticals ABTerminatedAcute Myeloid LeukemiaSweden, Poland, Czech Republic, United Kingdom
-
Astellas Pharma Global Development, Inc.Approved for marketingAcute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) MutationsUnited States, Canada, Japan
-
AbbVieSumitomo Pharma Oncology, Inc.CompletedAcute Myeloid Leukemia (AML)United States, Germany, United Kingdom
-
Jazz PharmaceuticalsIqvia Pty LtdCompleted
-
King's College Hospital NHS TrustLeukemia Research Fund; Department of Health; Elimination of Leukaemia FundUnknownLeukemia, Myeloid, AcuteUnited Kingdom
-
Imperial College LondonNot yet recruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Lymphoblastic LeukaemiaUnited Kingdom